Dec 1 (Reuters) - Belite Bio (BLTE.O), opens new tab said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study, sending its shares up over 15% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback